NUTX vs. TAK

Last updated Apr 1, 2026

Compare and contrast key facts about Nutex Health Inc (NUTX) and Takeda Pharmaceutical Company Limited (TAK).

Performance

NUTX vs. TAK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nutex Health Inc (NUTX) and Takeda Pharmaceutical Company Limited (TAK). The values are adjusted to include any dividend payments, if applicable.

NUTX vs. TAK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NUTX Nutex Health Inc	-42.27%	419.47%	17.37%	-90.53%	-95.25%
TAK Takeda Pharmaceutical Company Limited	18.79%	23.18%	-3.12%	-4.87%	8.50%

Fundamentals

EPS NUTX : $14.78 TAK : $36.10
PE Ratio NUTX : 6.43 TAK : 0.51
PS Ratio NUTX : 0.47 TAK : 0.01
Total Revenue (TTM) NUTX : $875.26M TAK : $4.49T
Gross Profit (TTM) NUTX : $444.28M TAK : $2.79T
EBITDA (TTM) NUTX : $274.31M TAK : $1.39T

Returns By Period

In the year-to-date period, NUTX achieves a -42.27% return, which is significantly lower than TAK's 18.79% return.

NUTX

• 1D: 4.55%
• 1M: -13.96%
• YTD: -42.27%
• 6M: -8.01%
• 1Y: 102.08%
• 3Y*: -14.40%
• 5Y*: —
• 10Y*: —

TAK

• 1D: 1.37%
• 1M: -1.23%
• YTD: 18.79%
• 6M: 26.50%
• 1Y: 27.35%
• 3Y*: 7.79%
• 5Y*: 3.44%
• 10Y*: 1.65%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NUTX vs. TAK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUTX

NUTX Risk / Return Rank: 72
NUTX Sharpe Ratio Rank: 72
NUTX Sortino Ratio Rank: 79
NUTX Omega Ratio Rank: 74
NUTX Calmar Ratio Rank: 72
NUTX Martin Ratio Rank: 64

TAK

TAK Risk / Return Rank: 78
TAK Sharpe Ratio Rank: 81
TAK Sortino Ratio Rank: 74
TAK Omega Ratio Rank: 73
TAK Calmar Ratio Rank: 80
TAK Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUTX vs. TAK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nutex Health Inc (NUTX) and Takeda Pharmaceutical Company Limited (TAK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NUTX	TAK	Difference
Sharpe ratio Return per unit of total volatility	0.88	1.30	-0.41
Sortino ratio Return per unit of downside risk	1.99	1.76	+0.23
Omega ratio Gain probability vs. loss probability	1.24	1.23	+0.01
Calmar ratio Return relative to maximum drawdown	1.54	2.24	-0.69
Martin ratio Return relative to average drawdown	2.40	5.82	-3.41
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NUTX vs. TAK - Sharpe Ratio Comparison

The current NUTX Sharpe Ratio is 0.88, which is lower than the TAK Sharpe Ratio of 1.30. The chart below compares the historical Sharpe Ratios of NUTX and TAK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NUTX	TAK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.88	1.30	-0.41
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.18	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.07	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.48	0.12	-0.60

Correlation

The correlation between NUTX and TAK is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NUTX vs. TAK - Dividend Comparison

NUTX has not paid dividends to shareholders, while TAK's dividend yield for the trailing twelve months is around 1.74%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NUTX Nutex Health Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TAK Takeda Pharmaceutical Company Limited	1.74%	4.24%	4.67%	4.41%	4.23%	2.98%	2.30%	4.20%	4.77%	2.81%	3.99%	2.92%

Drawdowns

NUTX vs. TAK - Drawdown Comparison

The maximum NUTX drawdown since its inception was -99.93%, which is greater than TAK's maximum drawdown of -54.25%. Use the drawdown chart below to compare losses from any high point for NUTX and TAK.

Drawdown Indicators

	NUTX	TAK	Difference
Max Drawdown Largest peak-to-trough decline	-99.93%	-54.25%	-45.68%
Max Drawdown (1Y) Largest decline over 1 year	-54.34%	-12.83%	-41.51%
Max Drawdown (5Y) Largest decline over 5 years	—	-30.09%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-54.25%	—
Current Drawdown Current decline from peak	-98.42%	-18.51%	-79.91%
Average Drawdown Average peak-to-trough decline	-97.24%	-23.22%	-74.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.90%	4.94%	+29.96%

Volatility

NUTX vs. TAK - Volatility Comparison

Nutex Health Inc (NUTX) has a higher volatility of 24.94% compared to Takeda Pharmaceutical Company Limited (TAK) at 6.63%. This indicates that NUTX's price experiences larger fluctuations and is considered to be riskier than TAK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUTX	TAK	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.94%	6.63%	+18.31%
Volatility (6M) Calculated over the trailing 6-month period	73.87%	13.96%	+59.91%
Volatility (1Y) Calculated over the trailing 1-year period	116.41%	21.17%	+95.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	135.16%	19.34%	+115.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	135.16%	23.02%	+112.14%

Financials

NUTX vs. TAK - Profitability Comparison

The chart below illustrates the profitability comparison between Nutex Health Inc and Takeda Pharmaceutical Company Limited over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NUTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a gross profit of 46.14M and revenue of 151.68M. Therefore, the gross margin over that period was 30.4%.

TAK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported a gross profit of 660.35B and revenue of 1.21T. Therefore, the gross margin over that period was 54.4%.

NUTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported an operating income of 39.37M and revenue of 151.68M, resulting in an operating margin of 26.0%.

TAK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported an operating income of 194.06B and revenue of 1.21T, resulting in an operating margin of 16.0%.

NUTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nutex Health Inc reported a net income of 11.83M and revenue of 151.68M, resulting in a net margin of 7.8%.

TAK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Takeda Pharmaceutical Company Limited reported a net income of 105.51B and revenue of 1.21T, resulting in a net margin of 8.7%.